The therapeutic future in headache

Neurological Sciences

Volumn 33, Issue SUPPL. 1, 2012, Pages

  Rapoport, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cluster headache prevention; Dihydroergotamine; Headache treatment; Migraine pipeline; Migraine treatment; Triptans

Indexed keywords

ALNIDITAN; BIBN 4096; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE[8-37]; CIS CAPSAICIN; CIVANEX; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE MESILATE; LOXAPINE; MOXIFLOXACIN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; NP 101; OLCEGEPANT; PLACEBO; PROCHLORPERAZINE; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; ZELRIX; ZOLMITRIPTAN;

APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ASTHENIA; BURNING SENSATION; CLUSTER HEADACHE; CONFERENCE PAPER; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSGEUSIA; EMERGENCY CARE; FOOT EDEMA; HEADACHE; HEART BLOCK; HUMAN; IONTOPHORESIS; LIVER TOXICITY; MENSTRUAL MIGRAINE; MIGRAINE; NERVE STIMULATION; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SPHENOPALANTINE GANGLION STIMULATION; TASTE DISORDER; THORAX PAIN; TRANSCRANIAL MAGNETIC STIMULATION; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CLUSTER HEADACHE; DIHYDROERGOTAMINE; FORECASTING; HEADACHE; HUMANS; TRANSDERMAL PATCH; TRYPTAMINES;

EID: 84864249094     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-1056-3     Document Type: Conference Paper

References (17)

1. Ramadan NM, Buchanan TM (2006) New and future migraine therapy. Pharmacol Ther 112:199-212 (Pubitemid 44301490)
2. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56 (Pubitemid 23009909)
3. Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698-705 (Pubitemid 41552545)
4. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110 (Pubitemid 38298990)
5. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304-1312 (Pubitemid 351550355)
6. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089-2090
7. Pierce M, Marbury T, O'Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartReliefTM transdermal technology. In: Data presented at the 50th annual scientific meeting of the American Headache Society, 28 June 2008
8. Acute Anti-Migraine Efficacy and Tolerability of Zelrix™, a Novel Iontophoretic Transdermal Patch of Sumatriptan. Paper presented at the American Academy of Neurology (AAN) 62nd Annual Meeting, April 2010
9. Rapoport AM, Freitag F, Pearlman S (2010) Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 24(11):929-940
10. Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177-3187
11. Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 48:355-367 (Pubitemid 351517766)
12. Silberstein SD, Kori SH, Aurora S et al (2010) LEVADEX TM , a novel orally inhaled treatment for acute migraine: Efficacy and tolerability results of a phase 3 study. In: 14th Congress of the International Headache Society; 2009 September 10-13, 2009; Philadelphia, PA, 2009
13. Luthringer R, Djupesland PG, Sheldrake CD et al (2009) Rapid absorption of sumatriptan powder and effects on the glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 61:1-10. doi: 10.1211ISSN0022-3573
14. Djupesland PG, Dočekal P, the Czech Migraine Investigators Group (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30(8):933-942 (Cephalalgia online first, published on March 17, 2010 as doi:10.1177/0333102409359314
15. Saper J, Klapper J, Mathew N et al (2002) Intransal civamide for the treatment of episodic cluster headaches. Arch Neurol 59:990-994 (Pubitemid 34640760)
16. Ansarinia M, Rezai A, Tepper S et al (2010) Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache 50:1164-1174
17. Rapoport A (2011) New frontiers in headache therapy. Neurol Sci 32:105-109